Plain-English translation of NCT06420076 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called cells for people with T-cell acute lymphoblastic leukemia (a blood cancer) that has either not responded to standard chemotherapy or has returned after treatment. CAR-T cell therapy involves taking your own immune cells, modifying them in the laboratory to better recognize and fight cancer cells, and then infusing them back into your body. The study will evaluate whether this medication is safe and effective for people with this serious condition.
When T-cell leukemia comes back or doesn't respond to standard chemotherapy, patients have very few treatment options and the outlook is very poor. This trial exists because researchers need to find safer and more effective treatments for people in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You will first receive two chemotherapy drugs given intravenously over a few days to prepare your body for the new cells. Then you will receive an infusion of the modified CAR-T cells through an IV over 10–20 minutes. If you respond well and tolerate the treatment without serious side effects, you may be eligible to receive up to two or three additional doses of the cells. The study will monitor you closely for safety and to see how well the treatment works, with a target enrollment of 60 patients.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China